



Immune Checkpoint Inhibitors in Cancer Focusing on Urogenital Tumors

Guest Editor:

Dr. Renate Pichler

Department of Urology,
Comprehensive Cancer Center
Innsbruck, Medizinische
Universität Innsbruck, Innsbruck,
Austria

Deadline for manuscript
submissions:

closed (8 November 2021)

Message from the Guest Editor

Dear Colleagues,

Immunotherapy alone or in combination with systemic or targeted therapy has revolutionized cancer treatment, becoming a therapeutic mainstay in various cancer entities, such as urogenital tumors. As an example, treatment with *Bacillus Calmette–Guérin* (BCG) belongs to the most successful cancer immunotherapies in high-risk, non-muscle-invasive bladder cancer for more than forty years. Although immunotherapy has dramatically expanded the therapeutic landscape in metastatic RCC and bladder cancer, biomarkers in predicting response to checkpoint inhibitors such as PD-L1 are still inconclusive, with discordant results. This Special Issue welcomes original articles and reviews about current treatment guidelines on checkpoint inhibition in urogenital cancers and novel molecular, genetic, and soluble biomarkers in predicting response and survival to checkpoint inhibitors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)